Business Wire

Smoke Free Sweden: Health Experts Criticize Misinformation Epidemic Threatening Public Health in Central Asia

8.3.2024 12:15:00 CET | Business Wire | Press Release

Share

“RAMPANT and reckless” misinformation about alternative nicotine products being spread throughout Central Asia is endangering lives, say leading international public health experts.

Uzbekistan’s state media recently reported baseless claims that “vaping contains thousands of chemicals… and is more harmful than smoking”1, following a ban on vaping products in neighboring Kazakhstan even after an independent expert report demonstrated that 165,000 lives could be saved2 in the country.

That retrograde step, endangering the lives of Kazakhstan’s 3.2 million smokers, has been copied by Kyrgyzstan (1.5 million smokers) and is now being recklessly championed in Uzbekistan (more than 3 million smokers and 2 million naswar users).

According to tobacco harm reduction movement, Smoke Free Sweden, such claims will cost lives and flies in the face of recent publications in other countries, such as those by the UK’s National Health Service3, and leading anti-smoking NGO ASH UK4.

The claims are also at odds with the approach of Sweden, which has effectively beaten smoking by allowing smokers to switch to alternatives. Sweden’s official smoking rate is 5.6%, on the threshold of being declared officially ‘smoke free’.

Leader of Smoke Free Sweden movement and former adviser to three WHO Directors-General Dr Delon Human said:

“Anti-vaping, or anti-nicotine pouch fear mongering campaigns, are effectively pro-smoking campaigns5, and they are on the rise in Uzbekistan, Kazakhstan and wider Central Asia, the resulting knee-jerk prohibitions undermine public health.

“Stifling regulation or worse, outright bans of less risky, non-combustible nicotine products are condemning millions of smokers to an unnecessary and avoidable premature death sentence due to continued smoking or consumption of harmful traditional naswar products

“Globally, these reduced-risk products are saving millions of lives by giving smokers an escape from deadly cigarettes. Countries such as Japan, New Zealand, Canada, and Sweden provide the proof which simply cannot be ignored.

“Attempts to bully the authorities of Uzbekistan and Central Asia into adopting deadly prohibitions must be rejected.”

Notes to editors

Smoke Free Sweden is led by Health Diplomats, a global network of public health experts committed to developing and delivering solutions to global health-related problems.

Sweden is about to become the first ‘smoke-free’ European country with a smoking rate of below 5 percent. This is a huge achievement and will be 16 years ahead of the 2040 EU target. Compared to the rest of Europe, Sweden has 44% fewer tobacco-related deaths, a cancer rate that is 41% lower, and 38% fewer deaths attributable to any cancer. This can be attributed to Sweden’s open attitude towards alternative products.

For more information on Sweden’s successful approach to becoming a smoke-free nation, please visit www.smokefreesweden.org.

1Xushboʻy dushmanning biz bilmagan jihatlari (youtube.com)

2d0e05b5eacc6a4f021b740d455a9ba49.pdf (thr.net)

3Vaping myths and the facts - Better Health - NHS (www.nhs.uk)

4ash.org.uk/uploads/Addressing-common-myths-about-vaping-ASH-brief.pdf?v=1691052025

5Harnessing tobacco harm reduction - The Lancet

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Press
Jessica Perkins
info@smokefreesweden.org

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye